Developing New Regimens
TB Medicines for All
Without improved, simpler, safer, and affordable cures for tuberculosis – in all its forms—we cannot eradicate the disease.
TB Alliance has the largest portfolio of potential TB treatments in the world. Our pipeline includes several late-stage drug regimens poised to make a transformative impact on the disease. Our product development strategy, whereby we develop drug combinations instead of individual drugs, shows promise to deliver treatments for drug-sensitive and drug-resistant TB, and unify TB therapy under a common, short and simple cure.
For the latest updates on our projects, please visit our Pipeline page or Clinicaltrials.gov. To schedule a briefing, please contact email@example.com. Consult our open access policy for more information on our commitment to information sharing and transparency.
Novel Regimens Poised for Impact
Focus on Nix-TB:
The Nix-TB study is among the first clinical trials to test a new regimen for XDR-TB. It is the first to test an all-oral drug regimen, comprised of drugs with minimal pre-existing resistance, which has the potential to shorten, simplify, and improve treatment for XDR-TB.
The Nix-TB regimen is comprised of three drugs with little or no known resistance. However, the true potential of such a regimen is even greater. Given the lack of pre-existing resistance to the drugs in this regimen, it shows potential to be a universal regimen — in other words, a single TB regimen that can treat virtually all patients with active TB — with a relatively simple and affordable regimen.
Advancing the Field
TB Alliance also works to advance the entire field of drug development through the release of several innovative tools, and its leadership role in the Critical Path to TB Drug Regimens (CPTR) Initiative. CPTR is a multi-sectoral initiative that is tackles a wide array of challenges associated with TB drug development, including product development, regulatory science, research resources, and drug sensitivity testing. TB Alliance lead’s CPTR’s “Drug Coalition” arm, which brings drug sponsors work together to assemble and test the most effective treatment regimens.